NCT07694570Not yet recruiting
Feasibility Study: Continuous ECG and Blood Pressure Monitoring With the M2VS Sensor System
Feasibility Study for Continuous Monitoring of Electrocardiogram (ECG) and Blood Pressure at the Chest and Upper Arm Using the M2VS System.
Source: ClinicalTrials.gov · Last updated 10 Jul 2026
Brief summary (registry, in English)
In this study, the investigators want to find out whether a new wearable sensor system, called the M2VS system, can reliably measure heart activity, blood pressure, and other vital signs over 24 hours during normal daily life. The investigators also want to compare the M2VS system with the standard devices currently used for long-term heart and blood pressure monitoring, such as a Holter ECG and an ambulatory blood pressure monitor (ABPM). This will provide an estimation of the accuracy of the M2VS system's ECG and blood pressure measurements compared to the standard devices. The aim of the study is to assess how reliable the M2VS system is in terms of data completeness and how comfortable it is to wear compared with the usual monitoring devices. In the future, the results of this study may help make the monitoring of heart and blood vessel diseases more comfortable and easier for patients.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 20 (estimated)
- First submitted
- 25 Jun 2026
- Start date
- 1 Jul 2026
- Primary completion date
- Aug 2026
- Lead sponsor
- University Hospital, Basel, Switzerland
- Diseases
- Atrial fibrillation, High blood pressure
- NCT number
- NCT07694570
What you commit to
- Study type: Observational
- Planned participants: 20
- From 1 Jul 2026 to the primary completion date, Aug 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Presence of other concurrent wearable devices at the same anatomical application site that could interfere with the M2VS system.
Other illness
- Pre-existing skin conditions at the application sites (medial upper arm or chest), such as extensive scarring, tattoos, open wounds, active inflammation, or severe oedema that could interfere with sensor coupling or signal quality.
- Known allergy to skin-contacting materials utilized in the M2VS system.
Other
- Insufficient knowledge of the German language, preventing adequate understanding of the project procedures and informed consent.
- Enrolment of the project leader, project staff, their family members, employees, or other dependent persons.
- Dermatological and Sensor Placement:
- Excessive hair at the application site that could interfere with sensor coupling or signal quality.
Who the study is looking for
- Written informed consent obtained prior to any project-specific procedures.
- Age 18 years or older at the time of enrolment.
- Ability to provide valid informed consent.
- Clinical indication for 24-hour Holter monitoring (Holter cohort) or 24-hour ABPM (ABPM cohort).
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University Hospital Basel Coordinator of this site? Confirm its status | Basel | Switzerland | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.